end-stage-kidney-disease
(2)
Alio
Alio is a Broomfield, Colorado medical technology company that builds a non-invasive, continuous remote patient monitoring platform for people with chronic conditions. Its flagship SmartPatch - the world's first non-invasive potassium monitor - is worn over a patient's vascular access site and tracks metrics such as potassium, hemoglobin, hematocrit, heart rate, skin temperature and auscultation sounds, sending clinician-ready data to care teams via a bedside hub, cloud and portal. Founded in 2012 (originally as Graftworx) by David Kuraguntla and Samit Gupta, Alio focuses first on end-stage kidney disease and dialysis patients, aiming to replace infrequent blood draws with continuous data and cut avoidable hospitalizations.
eGenesis
eGenesis is a Cambridge, Massachusetts clinical-stage biotechnology company using multiplex CRISPR gene editing to engineer pig organs that the human body will accept. Its EGEN platform makes dozens of edits to a porcine genome at once - removing pig antigens, adding human genes, and inactivating embedded retroviruses - to create kidneys, livers, and hearts intended to ease the global organ shortage. In 2024 its lead candidate became the basis of the world's first gene-edited pig kidney transplant in a living patient, and in 2025 the FDA cleared it for a formal clinical trial.